

# STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

### **LEVETIRACETAM**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
LEVETIRACETAM	SPRITAM		36266	GPI-14	
			31202	(7260004300G850	
			36046	7260004300G820	
			36265	7260004300G830	
				7260004300G840)	

#### **GUIDELINES FOR USE**

- 1. Does the patient have a diagnosis of partial-onset seizures and meet **ALL** of the following criteria?
  - The patient is 4 years of age or older
  - The patient is unable to swallow levetiracetam tablets
  - The patient had a trial of levetiracetam oral solution

If yes, approve for 12 months by GPID or GPI-14 for all strengths as follows:

250mg: #4 per day.
500mg: #4 per day.
750mg: #4 per day.
1000mg: #2 per day.

If no, continue to #2.

- 2. Does the patient have a diagnosis of myoclonic seizures in juvenile myoclonic epilepsy and meet **ALL** of the following criteria?
  - The patient is 12 years of age or older
  - Spritam will be used as adjunctive therapy
  - The patient is unable to swallow levetiracetam tablets
  - The patient had a trial of levetiracetam oral solution

If yes, approve for 12 months by GPID or GPI-14 for all strengths as follows:

250mg: #4 per day
500mg: #4 per day
750mg: #4 per day
1000mg: #2 per day

If no, continue to #3.

#### **CONTINUED ON NEXT PAGE**

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

2/17/2023 Page 1 of 3



# STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

### **LEVETIRACETAM**

# **GUIDELINES FOR USE (CONTINUED)**

- 3. Does the patient have a diagnosis of primary generalized tonic-clonic seizures and meet **ALL** of the following criteria?
  - The patient is 6 years of age or older
  - Spritam will be used as adjunctive therapy
  - The patient is unable to swallow levetiracetam tablets
  - The patient had a trial of levetiracetam oral solution

# If yes, approve for 12 months by GPID or GPI-14 for all strengths as follows:

- 250mg: #4 per day.
- 500mg: #4 per day.
- 750mg: #4 per day.
- 1000mg: #2 per day.

If no, do not approve.

DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **LEVETIRACETAM** (**Spritam**) requires the following rules be met for approval:

- A. You have ONE of the following diagnoses:
  - 1. Partial-onset seizures (type of seizure)
  - 2. Myoclonic seizures in juvenile myoclonic epilepsy (type of seizure in childhood)
  - 3. Primary generalized tonic-clonic seizures (type of seizure)
- B. If you have partial-onset seizures, approval also requires:
  - 1. You are 4 years of age or older
  - 2. You are unable to swallow levetiracetam tablets
  - 3. You had a trial of levetiracetam oral solution
- C. If you have myoclonic seizures in juvenile myoclonic epilepsy, approval also requires:
  - 1. You are 12 years of age or older
  - 2. Spritam will be used as adjunctive (add-on) therapy
  - 3. You are unable to swallow levetiracetam tablets
  - 4. You had a trial of levetiracetam oral solution
- D. If you have primary generalized tonic-clonic seizures, approval also requires:
  - 1. You are 6 years of age or older
  - 2. Spritam will be used as adjunctive (add-on) therapy
  - 3. You are unable to swallow levetiracetam tablets
  - 4. You had a trial of levetiracetam oral solution

(Denial text continued on next page)

# **CONTINUED ON NEXT PAGE**

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

2/17/2023 Page 2 of 3



# STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

### **LEVETIRACETAM**

# **GUIDELINES FOR USE (CONTINUED)**

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

#### **RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Spritam.

### **REFERENCES**

• Spritam [Prescribing Information]. Blue Ash, OH: Aprecia Pharmaceuticals LLC; January 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A Created: 11/22

Commercial Effective: 04/01/23 Client Approval: 02/23 P&T Approval: 10/22

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

2/17/2023 Page 3 of 3